Boston Scientific Corporation (BSX) has been struggling due to unfavorable currency movement and macroeconomic woes. Strong competitors in the large medical device market also pose a tough challenge for Boston Scientific. The stock carries a Zacks Rank #4 (Sell) currently.The industry-wide trend of challenging macroeconomic conditions in the form of inflation, disruptions in economic activity, global supply chains and labor markets, volatile financial market dynamics and significant volatility in price and ...

MARLBOROUGH, Mass., April 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation (PFA) Catheter* for the treatment of patients with paroxysmal and persistent atrial fibrillation (AF). The FARAVIEW technology and the FARAWAVE Nav catheter expand the capabilities of the FARAPULSE™ PFA System through integration with our cardiac mapping system. In a pul ...

MARLBOROUGH, Mass., April 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2024, on Wednesday, April 24, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on A ...

Boston Scientific (BSX) is gaining traction in the emerging markets. New regulatory approvals and accretive acquisitions bode well for its long-term growth. Yet, an unfavorable currency movement and macroeconomic concerns are major dampeners. The stock carries a Zacks Rank #3 (Hold) at present.BSX successfully continues with its expansion of operations across different geographies outside the United States. In 2022, 40% of the company’s consolidated revenues came from international regions.The company is al ...

Boston Scientific Corporation (BSX) achieved a milestone with the recent FDA approval for its AGENT Drug-Coated Balloon (DCB). This marks the first drug-coated coronary balloon available in the United States.This approval signals a key advancement in the treatment landscape for coronary in-stent restenosis (ISR), a challenging condition characterized by the narrowing of stented vessels due to plaque or scar tissue formation. With this, Boston Scientific is expected to broaden its Interventional Cardiology ( ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...

First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a ...

MARLBOROUGH, Mass., Feb. 27, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) (the "Company") today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has completed a public offering of €750,000,000 aggregate principal amount of 3.375% notes due 2029 and €1,250,000,000 aggregate principal amount of 3.500% notes due 2032 (collectively, the "Notes"). The Notes are fully and unconditionally guaranteed by the Company. Application has been made for the Notes t ...

Have you been paying attention to shares of Boston Scientific (BSX) ? Shares have been on the move with the stock up 8.7% over the past month. The stock hit a new 52-week high of $67.32 in the previous session. Boston Scientific has gained 15.3% since the start of the year compared to the 7.8% move for the Zacks Medical sector and the 6.5% return for the Zacks Medical - Products industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our ea ...

The Boston Scientific logo is being displayed on a smartphone with a broken screen in Athens, ... [+] Greece, on February 2, 2024. (Photo by Nikolas Kokovlis/NurPhoto via Getty Images)NurPhoto via Getty ImagesBoston Scientific BSX (NYSE: BSX) reported its Q4 results last month, with revenues and earnings comfortably beating the street estimates. The company reported revenue of $3.7 billion and adjusted earnings of $0.55 per share, compared to the consensus estimates of $3.6 billion and $0.51, respectively. ...